MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd, India's top drugmaker by sales, said on Saturday it had agreed to sell two divisions marketing central nervous system drugs to Strides Arcolab Ltd for 1.65 billion rupees ($25 million).
Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd, in July said it may sell low-margin businesses it deemed do not hold long-term value.
Under the latest deal, Strides Arcolab will take over Ranbaxy's Solus and Solus Care divisions, Sun Pharma said in a statement.
($1 = 65.8582 rupees)
(Reporting by Devidutta Tripathy; Editing by Christopher Cushing)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app